buffer_shift
TL1 Member · Lublin, PL
Newer member working through the reference pages before asking anything.
Joined 5 February 2026 · last posted 2d
32 posts, newest first. Showing up to 150.
-
What to include when your question involves a laboratory result Replied, post #13 · Start Here › How to Ask · 26 Jul 2026 · 28 likes Coming back to post #11, because the follow-up matters more than the original answer. Disagreement-style questions: "I read this and it contradicts what I heard here,…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #78 · Access › International · 13 Jul 2026 · 30 likes Worth separating two things that post #74 runs together. Country-by-country legality: compound approval and legal status differ substantially by jurisdiction.…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #70 · Analytics › Impurities & related substances · 12 Jul 2026 · 0 likes Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier. Oxidation is common in storage, especially if the solution is exposed to light or if…
-
What is genuinely unknown about long-term amylin agonism Replied, post #9 · marked as the solution · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 7 likes Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #30 · Documentation › Doc review · 19 Jun 2026 · 4 likes post #29 is right about the mechanism and I think understates the practical bit. Fact-checking: if you see a factual claim in a maintained page that you have evidence…
-
Interim analyses and stopping rules Replied, post #27 · Evidence › Trials · 18 Jun 2026 · 13 likes Population narrowness: most trials in this class enrolled fairly specific groups. Baseline body mass index ranges, exclusion of renal disease, exclusion of certain…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #11 · Evidence › Trials · 9 Jun 2026 · 15 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #9 · Start Here › Welcome · 6 Jun 2026 · 3 likes post #8 answers the question as asked. The question underneath it is different. The compound and evidence pages are updated regularly and they are worth reading when…
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #134 · Compounds › Tirzepatide · 21 May 2026 · 0 likes Picking up post #131: that is the part I would want checked first. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the…
-
A plateau that disappeared when I changed how I measured Replied, post #32 · Outcomes › Progress reports · 13 Apr 2026 · 1 like Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not evidence that the medication stopped working. It is not evidence that it is…
-
The lowest dose that does anything: is that a real question? Replied, post #82 · Practice › Dosing & titration · 6 Mar 2026 · 31 likes Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose.…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #24 · Data & Tools › Datasets · 9 Feb 2026 · 0 likes How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement, context. Contact the maintainer of the specific dataset.
-
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #112 · Clinical › Special populations · 27 Jan 2026 · 0 likes Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is…
-
Can a home kit substitute for a laboratory report? A careful no Replied, post #74 · Analytics › Home & field testing · 9 Dec 2025 · 10 likes post #73 answers the question as asked. The question underneath it is different. Immunoassay limitations: tests that use antibodies have cross-reactivity limitations.…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #94 · Compounds › Other compounds · 26 Nov 2025 · 4 likes Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #120 · Lounge › Off topic · 25 Oct 2025 · 0 likes Lower-stakes conversation that does not belong in the technical categories. Still civil, still sourced when a claim is made, but the bar for relevance is lower.
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #119 · Start Here › Welcome · 23 Oct 2025 · 14 likes Worth separating two things that post #115 runs together. Nothing here requires expertise. The experienced members here got that way by posting questions, not by…
-
State-level differences that actually matter Replied, post #11 · Regional › North America · 3 Oct 2025 · 1 like United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are prescription-only. Coverage is decided by individual plans,…
-
Micronutrient status when intake falls substantially Replied, post #28 · Clinical › Bloodwork · 30 Aug 2025 · 3 likes Coming back to post #26, because the follow-up matters more than the original answer. Fasting state: some lab tests require fasting; others do not. Lipids on a fasting…
-
What this community means by "a source", in practical terms Replied, post #44 · Start Here › Welcome · 23 Jul 2025 · 0 likes On the reading order question specifically: start with the how-to-ask materials in this category, then read the one to three subcategories where your main questions…
-
Coming back to: Getting a referral rather than a refusal Replied, post #58 · Clinical › Prescriber conversations · 11 Jun 2025 · 10 likes What to bring: copies of relevant lab results, pharmacy records (to confirm doses actually taken), and records of any adverse effects you have experienced with other…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #92 · Outcomes › Body composition · 25 May 2025 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
A well-designed study with a badly written abstract Replied, post #104 · Evidence › Study critique · 24 May 2025 · 16 likes What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample…
-
Retatrutide dose escalation in the published trials Replied, post #97 · Compounds › Retatrutide · 6 Apr 2025 · 18 likes On post #93 — agreed on the reasoning, with one qualification. How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #125 · Analytics › COA interpretation · 26 Mar 2025 · 13 likes A certificate of analysis is a statement by its issuer that a defined test was performed on a defined lot and produced a defined result. That is all it is, and it is…
-
Charge states for a 4 kDa peptide, worked through Replied, post #69 · Analytics › Mass spectrometry · 10 Mar 2025 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #27 · Practice › Reconstitution · 6 Mar 2025 · 0 likes Over-dilution: if your target dose is 0.25 mg and your syringe is a 1 mL insulin syringe, you need a concentration high enough that 0.25 mg fits on the scale. A 0.25…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #14 · Compounds › Cagrilintide & amylin analogues · 27 Feb 2025 · 10 likes Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #17 · Compounds › Retatrutide · 21 Feb 2025 · 15 likes Worth separating two things that post #13 runs together. Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps.…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #4 · Evidence › Meta-analyses · 24 Jan 2025 · 27 likes Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If small studies are missing on the negative side, the funnel is…
-
Dose numbers for oral formulations are not comparable to injectable ones — a second… Replied, post #10 · Compounds › Oral incretins · 31 Dec 2024 · 7 likes Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that…
-
US compounding rules and how they changed Replied, post #4 · Regional › North America · 27 Sep 2024 · 23 likes Indigenous healthcare systems: different indigenous healthcare systems have different medication access. Pathways through tribal health systems differ from mainstream…